Verge Medical, a company focused on vascular care, has acquired the RoVo system and its Temporary Occlusion Embolectomy (TOE) tech from 2MG Medical.

The RoVo system addresses the risk of distal embolization with its novel TOE technique, which temporarily blocks downstream blood flow through compression while a vacuum-activated catheter is advanced and rotated to create a patented “vortex” effect that efficiently captures and removes debris.

The acquisition boosts Verge’s growing portfolio of targeted, setting-specific solutions for coronary and peripheral vascular interventions.

“The RoVo System exemplifies Verge Medical’s mission to provide targeted solutions that are aligned with today’s clinical, workflow and reimbursement realities,” said Mike Buck, CEO of Verge Medical. “RoVo is a smart, accessible technology designed to empower physicians to manage distal embolization with greater confidence. We look forward delivering innovative, practical tools like RoVo into the hands of physicians who need them most.”

RoVo joins the company’s growing portfolio, which includes the FLAS aorto-ostial angioplasty system, which has been used in over 25,000 procedures to date. It also includes the Wavella specialty infusion catheter for venous therapy.

Once FDA clearance is achieved, the RoVo system and its TEO technique bolster Verge’s commitment to advancing vascular care through practical, physician-driven innovation designed to improve safety, efficiency, and outcomes.